A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection
Phase of Trial: Phase II
Latest Information Update: 22 Nov 2017
At a glance
- Drugs Glecaprevir (Primary) ; Pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors AbbVie
- 15 Nov 2017 Planned primary completion date changed from 26 Apr 2019 to 13 Jul 2020.
- 07 Sep 2017 Planned End Date changed from 27 Jan 2020 to 13 Jul 2020.
- 10 Jun 2017 Biomarkers information updated